Annual report pursuant to Section 13 and 15(d)

Stockholders' Equity (Details Narrative)

v3.19.3.a.u2
Stockholders' Equity (Details Narrative) - USD ($)
 2 Months Ended 12 Months Ended
Sep. 30, 2019
May 25, 2018
Jun. 29, 2018
Dec. 31, 2019
Aug. 31, 2019
Dec. 31, 2018
Preferred stock, shares authorized       1,000,000 10,000,000  
Common stock, shares authorized       100,000,000 350,000,000 350,000,000
Debt conversion price per share       $ 14.28    
PoC Capital, LLC [Member]            
Number of common stock issued   113,280        
Warrants to purchase common stock   113,280        
Number of common stock, forfeited 56,640          
Warrants to purchase common stock, forfeited 56,640          
Purchase price per unit   $ 15.89        
Warrant exercise price per share   $ 19.07        
Amount paid to placement agent   $ 108,000        
Issued placement agent warrants to purchase shares   6,797        
Warrant term   3 years        
Transaction costs incurred   $ 60,457        
Clinical trial funding commitment $ 900,000 $ 1,800,000        
2018 Private Placement Transactions [Member]            
Number of units sold     200,369      
Purchase price per unit     $ 15.89      
Gross proceeds from unit sold     $ 3,200,000      
Warrant exercise price per share     $ 19.07      
Amount paid to placement agent     $ 167,526      
Issued placement agent warrants to purchase shares     12,021      
Warrant term     3 years      
Transaction costs incurred     $ 141,304      
Sale of stock price per share       $ 17.50    
Number of common stock to be issued       28,971    
Number of common stock to be issued, value       $ 506,993    
Pledge Agreement with PoC [Member]            
Number of common stock, pledged   56,640        
Warrants to purchase common stock, pledged   56,640